NYBA 21st Annual Meeting
Biopharmas' Commercialization Model is Slow to Evolve, Adapt
By Michael Harris
Friday, May 4, 2012
NEW YORK Revenue losses due to patent expirations, an increasingly complicated regulatory landscape and erratic results in getting drugs to market are key dynamics forcing biopharmas to take a look in the mirror and acknowledge the need for change, according to a panel at the New York Biotechnology Association 21st annual meeting this week.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.